Teva Makes A Specialty M&A Play In Deal To Buy Auspex

The Israeli generic drug company will gain a lead drug in development for movement disorders, including chorea associated with Huntington’s disease, with the $3.5 billion acquisition of Auspex Pharmaceuticals.